Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 28, 2025-

New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease

Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.

AAIC25: Cognito neuromodulation therapy slows decline in Alzheimer’s disease

Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate Alzheimer’s disease.The post AAIC25: Cognito neuromodulation therapy slows decline in Alzheimer’s disease appeared first on Medical Device Network.

Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)

Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ — Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the […] The post Alamar Biosciences Showcases…

Using the Syn-One Test for Earlier Detection in Neurodegenerative Diseases: Todd Levine, MD

At AAIC 2025, the chief medical officer at CND Life Sciences discussed recent progress in detecting neurodegenerative diseases earlier using tools like the Syn-One Test. [WATCH TIME: 3 minutes]

Neurogen Biomarking Virtual Care Ecosystem Cuts Time to Alzheimer’s Intervention by 4.5 Years, AAIC 2025 Presentation Findings Show

Progress in validating in-home blood test, combined with cognitive assessment and specialty virtual care, break through barriers to early detection Key Takeaways Findings from breakthrough approach to early detection for Alzheimer’s disease (AD) has the potential to reduce time from earliest development of symptoms to care by 4.5 years are presented at the AAIC 2025. Results show strong correlation between TASSO vs. traditional phlebotomist blo…